breast-cancer
Researchers are launching a new project to study how aggressive breast cancers interact with and suppress the immune system. The project will use real patient samples to study tumor evolution and identify new biomarkers that reveal how the cancer progresses. The ultimate goal is to translate…
breast-cancer
Ductal carcinoma in situ (DCIS) is a pre-invasive breast condition often treated with surgery, but its natural history and optimal management are debated. This study found that women who chose active surveillance for DCIS had ipsilateral invasive breast cancer survival rates similar to those who…
breast-cancer
This study with 10-year follow-up confirmed that radiotherapy tailored to pathological nodal response (rather than standardized protocols) in breast cancer achieves very low locoregional recurrence rates—less than 3% of patients experienced recurrence, most within the first 5 years.
breast-cancer
Older radiation techniques for left-sided breast cancer inadvertently exposed the heart to significant doses, raising cardiovascular disease risk years later. This study examined whether modern external beam radiation therapy (EBRT) techniques—using more precise delivery methods—have reduced this…
melanoma
Bile acids (BAs) are significantly enriched in melanoma and breast cancer tumor microenvironments. BA enrichment drives tumor aerobic glycolysis and immune evasion by activating and stabilizing the FXR-RARα complex, upregulating glycolytic pathways and impairing anti-tumor immunity. BA depletion…
breast-cancer
Retrospective Chinese study of 318 women with stage I-III HR+ breast cancer: early structured psychological care (≥3 sessions within 3 months of surgery) was associated with significantly better 1-year endocrine therapy adherence (OR 2.15) vs. no/minimal care. Good adherence: 77% (early structured)…
breast-cancer
Patient samples from a Phase II neoadjuvant talazoparib trial (NCT03499353) revealed two resistance mechanisms: (1) BRN2 overexpression activating ATR/RAD51 and STAT3 pathways to restore HR repair (reversible with ATR and STAT3 inhibitors); (2) pre-existing SHLD2-deficient tumor subclone expansion.…
breast-cancer
Using cancer spheroid-3D matrix models, scRNA-seq, and human tissue explants, researchers overturned the dogma that amoeboid cancer cells bypass the need for proteinases. CRISPR/Cas9 deletion of MMP14 abolished tissue-invasive activity in both mesenchymal and amoeboid modes. MMP14-deleted cells…
breast-cancer
Mitocytosis expels damaged mitochondria via migrasomes, conferring resistance to mitochondria-targeted therapy. Researchers developed RH-NPs dual nanoplatform: TL/RH-NPs damage tumor mitochondria; CGT/RH-NPs block mitocytosis by inhibiting integrin signaling when cells attempt mitochondrial…
breast-cancer
TNBC historically had few targeted options and the worst breast cancer outcomes. Recent advances include checkpoint inhibitors improving outcomes for PD-L1-positive metastatic disease, and ADCs (sacituzumab govitecan, trastuzumab deruxtecan) moving earlier in treatment algorithms. Molecular…
breast-cancer
New SOAT (SLC10A6) inhibitors (compounds 12 and 24) markedly reduced DHEAS uptake in MCF-7 breast cancer cells, decreasing intracellular estradiol synthesis and suppressing estrogen-dependent proliferation without cytotoxicity to normal cells. SOAT is an upstream regulator of intracrine estrogen…
breast-cancer
Retrospective study of 44 HER2-positive breast cancer patients treated with 12-week neoadjuvant weekly paclitaxel + carboplatin + trastuzumab + pertuzumab (12wTCHP): 61% pCR rate (75% ER-negative, 54% ER-positive), only 2 recurrences (5%) at 30-month median follow-up, no treatment deaths.…